INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 203 filers reported holding INOVIO PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.42 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | -100.0% | 2 | -99.9% | 0.00% | – |
| Q2 2023 | $1 | -50.0% | 2,083 | 0.0% | 0.00% | – |
| Q1 2023 | $2 | -33.3% | 2,083 | 0.0% | 0.00% | – |
| Q4 2022 | $3 | -99.9% | 2,083 | 0.0% | 0.00% | – |
| Q3 2022 | $4,000 | 0.0% | 2,083 | -2.0% | 0.00% | – |
| Q2 2022 | $4,000 | -42.9% | 2,126 | +1.9% | 0.00% | – |
| Q1 2022 | $7,000 | -75.9% | 2,087 | -63.9% | 0.00% | -100.0% |
| Q4 2021 | $29,000 | -73.1% | 5,788 | -61.8% | 0.00% | -80.0% |
| Q3 2021 | $108,000 | -25.0% | 15,151 | -2.6% | 0.01% | -16.7% |
| Q2 2021 | $144,000 | 0.0% | 15,558 | +0.2% | 0.01% | -14.3% |
| Q1 2021 | $144,000 | +3.6% | 15,531 | -1.2% | 0.01% | -12.5% |
| Q4 2020 | $139,000 | -18.7% | 15,722 | +6.5% | 0.01% | -27.3% |
| Q3 2020 | $171,000 | -19.0% | 14,767 | +88.5% | 0.01% | -26.7% |
| Q2 2020 | $211,000 | – | 7,836 | +783500.0% | 0.02% | – |
| Q1 2020 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 1 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |